Evaluating Vaporized Cannabinoid Therapy in Multiple Sclerosis: Findings from a Prospective Single-Center Clinical Study.

J Clin Med · 2025 · PMC11943353 · PMID 40142928

Europe PMC DOI

hedged sentence

0.5670

closest p · 11.3× alpha

0.5670

boldest claim

The sentences

did not reach statistical significancep = 0.567not close (p > 0.1)

However, comparisons between baseline and three months (3.89 ± 1.26), as well as between three- and six-month intervals, did not reach statistical significance ( p = 0.567, 95% CI [−0.08, 0.27] and p = 0.282, 95% CI [−0.06, 0.30], respectively) ( Table 3 and Figure 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.